Abstract: The present invention demonstrates that p38MAPK inhibitor induces low density lipoprotein receptor expression 6-8 fold, and further provides the application of such inhibitor in the treatment of hypercholesterolemia.

Abstract: A method for preparing nondeliquescent crystalline calcium pantothenate which comprises the steps of: (1) stirring a supersaturated aqueous solution containing calcium pantothenate in a ratio of 60% (W/W) or more, for example, by using a grinder mill, to obtain a crystal suspension; and (2) drying the suspension. A nondeliquescent crystalline calcium pantothenate which is substantially free from an organic solvent can be efficiently prepared.

Abstract: Elevated levels of homocysteine have been implicated as an important risk factor for cardiovascular and other diseases. A composition for decreasing levels of plasma homocysteine and a method for administering the composition are provided the composition containing dextromethorphan (DM), folic acid and vitamins B6 and B12. The composition provides a synergistic therapeutic effect so that lower amounts of the above ingredients may be employed to minimize any undesirable side effects caused by the use of high levels of a component such as DM. Preferred compositions for cardiovascular diseases further include lecithin, vitamin E, beta-carotene, procyanidins/flavonoids, trimethylglycine, garlic oil and minerals. Other compositions for treating glaucoma include bilberry, bioflavonoids and beta-carotene and for treating tardive dyskinesia include an antioxidant such as grape seed extract and pine bark extract, lecithin and oligomeric proanthocyanidins.

Abstract: A forming oil-in-water emulsion in the form of a cream comprising, in an aqueous medium, at least: a) from 5 to 20% of an exclusively nonionic surfactant system comprising at least one foaming nonionic surfactant; b) from 10 to 50% of an oily phase containing at least one water-insoluble oil whose solubility parameters dD, dP and dH according to Hansen's solubility space satisfy the conditions: 15.5 (J/cm3)½≦dD≦18.0 (J/cm3)½ and 0 (J/cm3)½≦dA≦6.5 (J/cm3)½ with dA=(dP2+dH2)½ c) and, as a gelling agent, at least one crosslinked homopolymer or copolymer formed from at least one cationic or anionic monomer containing ethylenic unsaturation and from a crosslinking agent containing polyethylenic unsaturation. This composition is useful in cosmetics, dermatology and hygiene as a base for cleansing products for the skin, the hair, the mucous membranes and the scalp.

Abstract: Disclosed is a method for treatment of external secretion disorders, which comprises administering a fatty acid derivative to a subject in need of said treatment. The method of the present invention is useful for treatment of at least one condition selected from hypolacrimation including disorder of basal tear secretion, dry-eye syndrome, hyposalivation and dry-mouth syndrome.

Abstract: Supplemented food formulations are disclosed. A gelatin has a composition comprising an effective amount of an antioxidant having anti-aging properties, an effective amount of a carnitine having anti-aging properties, a carbohydrate source for calories, an effective amount of at least one B vitamin, and flavors.

Abstract: Methods for treating mammals for neurointoxication are provided comprising treating the mammal with a xenon-containing gas. Methods of providing neuroprotection in mammals are also disclosed comprising administering therapeutically effective amounts of xenon, preferably in combination with pharmaceutically acceptable carriers, diluents or excipients.

Abstract: A pharmaceutical composition containing a glycogen phosphorylase inhibitor of Formula I or IA as defined herein is administered to a mammal to treat infection.

Abstract: Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds.

Abstract: This invention relates to a composition for inducing smoking cessation comprising as active ingredient alkaloids from Radix ipecauanhae. In smoking cessation program using the composition, the considerable number of volunteers participated in the program became nausea and thus ultimately to have no craving for smoking.

Abstract: The present invention relates to several novel acridone-derived compounds of of formula (I) or (II). These compounds are potent anti-viral agents, useful in the treatment of viral diseases, such as Human Immunodeficiency Virus. In addition, these compounds are anti-neoplastic agents useful in the treatment of various forms of cancer. wherein R1 and R2 are independently —H, —OH, amino, alkylamino, dialkylamino, alkoxy, alkyl, haloalkyl or halogen; n is 2 to 6, X and X′ are independently —N or —NO2; Y and Y′ are independently —N or —CH, or —H; and the double-slash represents a double bond or no bond.

Abstract: Efficacious remedies for male sterility which are in the form of preparations containing as the active ingredient an adenosine A1 antagonist.

Abstract: This invention relates to methods and pharmaceutical compositions useful in the treatment of conditions that are responsive to the elevation of testosterone levels in the body and the use of estrogen agonists/antagonists for the manufacture of medicaments for the treatment of conditions that are responsive to the elevation of testosterone levels in the body. The compositions are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. These compositions are effective in treating male subject sexual dysfunction and timidity in female subjects including post-menopausal women and are effective in increasing libido in female subjects including post-menopausal women. In the case of male subject sexual dysfunction, the compositions may also include a compound which is an elevator of cyclic guanosine 3′,5′-monophosphate (cGMP).

Abstract: The present invention provides a citral acetal capable of sustaining a lemon aroma unique to citral and a perfume composition comprising the citral acetal, as well as an LDH inhibitor and a deodorant, cosmetics and a skin agent for external application, comprising the LDH inhibitor. The citral acetal of the present invention is represented by formula (1): wherein the wavy line represents a cis and/or trans form, and R represents a C1, to C9, linear or branched alkyl group.

Abstract: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.

Abstract: The present invention concerns a product for topical application, capable of releasing a hydroxy acid on the skin, containing a lipase as enzyme and at least one precursor of the hydroxy acid. The precursor is an ester of the hydroxy acid, containing at least one ester functional group having a saturated or unsaturated, linear or branched chain and from 2 to 25 carbon atoms. According to a preferred form, the precursor and the lipase are packaged so as not to be in contact with one another until the time of application to the skin.

Abstract: Disclosed herein are compositions to meet the needs of individuals, including humans and pets. Nutritional beverages, powders to make the same, a pudding and a nutritional bar are disclosed whose compositions include the R-&agr;-lipoic acid in the amount of 0.12 grams to 1.5 grams and L-carnitine in the amount of 0.12 grams to 3 grams in addition to the usual composition. Optionally, effective amounts of coenzyme Q and/or creatine also are added. These additional components fight age-related declines in mitochondrial function which result in less energy and other signs of aging.

Abstract: Novel CycloHexenyl-Ethyl-Thiourea (CHET) compounds as inhibitors of reverse transcriptase and effective agents for the treatment of HIV infection, including mutant, drug-sensitive, drug-resistant, and multi-drug resistant strains of HIV.

Abstract: Dermatitis can be treated by the administration of &Dgr;5-androstene-3&bgr;-ol-7,17 dione and metabolizable precursors thereof, such as &Dgr;5-androstene-3&bgr;-acetoxy-7,17 dione, to the skin.

Abstract: Disclosed are novel thickened organic fluid/surfactant compositions that are uniform, flowable and dispersible in water. Also disclosed are novel pesticidal compositions comprising a pesticide and the novel thickened organic fluid/surfactant composition.